The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU) located in London, which is responsible for the scientific evaluation, supervision and safety monitoring of medicines for use in the EU. EMA protects human and animal health in 28 EU Member States (MS’s), as well as the countries of the European Economic Area, by ensuring that all medicines available on the EU market are safe, effective and of good quality.
On the 6th of July, the Agency has stated in their website that “its procedures and work streams are not affected by the outcome of the referendum” and that they “will continue its operations as usual, in accordance with the timelines set by its rules and regulations”.
As there is no precedent in the EU for this situation, at this moment it is not possible to know the implications for the seat and operations of EMA. Some MS’s have expressed their interest to host the Agency in the future, but this decision will be taken by agreement between representatives of the MS’s
EMA welcomes the interest expressed by some Member States to host the Agency in future. The decision on the seat of the Agency will however not be taken by EMA, but will be decided by common agreement among the representatives of the Member States. We are confident that the Member States will take the most appropriate decision on EMA’s location and arrangements in due course, taking also into account the complex political and legal environment generated by the outcome of the UK referendum.
For the time being, as stated by the Agency, “its 890 employees and all the European experts contributing to EMA’s work will continue to focus on EMA’s mission”.